Risk Factors for Colorectal Cancer in Patients With Inflammatory Bowel Disease Undergoing Surveillance: a Prospective Cohort Study
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01464151 |
|
Recruitment Status :
Recruiting
First Posted : November 3, 2011
Last Update Posted : October 26, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Both ulcerative colitis and Crohn's colitis are associated with an increased risk of developing colorectal cancer (CRC). Although the increased risk of CRC in colitis patients is well established, several studies show that the risk varies widely between patients, depending on the presence of risk factors. Recently, several of these risk factors were implemented in the updated British guidelines for surveillance which are now used to determine surveillance intervals in our center. The new guideline recommends stratification of patients in a high, medium or low risk group depending on the presence of clinical and endoscopic risk factors and to adjust the surveillance interval accordingly. Although these guidelines provide a first step towards an individualized surveillance regimen, current data regarding risk factors for IBD-associated CRC are solely based on retrospective studies. Prospective data on the phenotype and genotype reliably predicting the risk of CRC is needed to further optimize surveillance in the future.
Objectives:
- To confirm established and identify new predictive factors for colorectal cancer in a prospective cohort of IBD patients undergoing regular surveillance. Dysplasia or colorectal cancer will be the primary outcome.
- To provide evidence that mucosal healing results in a significant reduction of colorectal dysplasia/neoplasia in IBD patients and that this is associated with 5-ASA or anti-TNF maintenance therapy.
- Study the expression of several tumor markers in biopsies, blood and faeces at baseline and determine whether expression of these markers can predict dysplasia or colorectal cancer development during follow-up.
| Condition or disease |
|---|
| Inflammatory Bowel Disease Colorectal Cancer |
| Study Type : | Observational |
| Estimated Enrollment : | 700 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Official Title: | Risk Factors for Colorectal Cancer in Patients With Inflammatory Bowel Disease Undergoing Surveillance: a Prospective Cohort Study |
| Study Start Date : | July 2011 |
| Estimated Primary Completion Date : | July 2018 |
| Estimated Study Completion Date : | December 2018 |
| Group/Cohort |
|---|
|
Patients with inflammatory bowel disease
patients with a diagnosis of ulcerative colitis, Crohn's colitis or indeterminate colitis between 18 and 70 years of age. Patients should have an indication for surveillance according to the current guidelines, which means a disease duration of at least 8 years and involvement of at least 30% of the colon.
|
- low- or high grade dysplasia or colorectal cancer during follow-up [ Time Frame: 5 years ]
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Diagnosis of ulcerative colitis, crohn's colitis or indeterminate colitis
- Disease duration ≥ 8 years
- Inflammation of at least 30% of colonic mucosa at some point between IBD diagnosis and inclusion
- Age 18 - 70 years
- Signed informed consent
Exclusion Criteria:
- High grade dysplasia or colorectal cancer before inclusion
- subtotal or total colectomy before inclusion
- Clotting disorder or use of anticoagulants that can not be temporarily discontinued
- Serious comorbidities which prevent performing a colonoscopy
- Limited life expectancy
- Clinical or endoscopical disease activity (at the discretion of the treating physician)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01464151
| Netherlands | |
| AMC | Recruiting |
| Amsterdam, Netherlands | |
| Contact: E. Dekker, MD, PhD 020 566 9111 | |
| LUMC | Recruiting |
| Leiden, Netherlands, 2333 ZA | |
| Contact: A.E. van der Meulen, MD, PhD 071 526 9111 | |
| Principal Investigator: A.E van der Meulen, MD, PhD | |
| Radboud UMC | Recruiting |
| Nijmegen, Netherlands | |
| Contact: F. Hoentjen, MD, PhD 024 361 1111 | |
| UMC Utrecht | Recruiting |
| Utrecht, Netherlands, 3584 CX | |
| Contact: Joren ten Hove, MD +31 887550722 j.r.tenhove-2@umcutrecht.nl | |
| Sub-Investigator: Joren ten Hove, MD | |
| Responsible Party: | B. Oldenburg, MD, PhD, UMC Utrecht |
| ClinicalTrials.gov Identifier: | NCT01464151 History of Changes |
| Other Study ID Numbers: |
11-050 |
| First Posted: | November 3, 2011 Key Record Dates |
| Last Update Posted: | October 26, 2016 |
| Last Verified: | October 2016 |
Keywords provided by B. Oldenburg, UMC Utrecht:
|
IBD colitis dysplasia colorectal cancer |
Additional relevant MeSH terms:
|
Inflammatory Bowel Diseases Colorectal Neoplasms Intestinal Diseases Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site |
Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Rectal Diseases Gastroenteritis |